Neurocrine Biosciences' ERUDITE™ Phase 2 Data on Luvadaxistat for Cognitive Impairment in Schizophrenia
Neurocrine Biosciences Reports ERUDITE™ Phase 2 Findings
Neurocrine Biosciences has shared an update regarding Luvadaxistat, its investigational treatment for cognitive impairment linked to schizophrenia. Results from the ERUDITE™ Phase 2 study indicate that the treatment did not achieve its primary endpoint. This outcome was significantly affected by variability in cognition among the participants involved in the trial.
Implications of Study Findings
The findings suggest challenges in the development of Luvadaxistat as a viable treatment for cognitive impairment associated with schizophrenia. Researchers will need to analyze the data further to understand the implications of these results and explore future directions.
Further Research Needed
As the complexity of schizophrenia and cognitive impairment persists, ongoing research is critical in assessing potential therapeutic avenues. Neurocrine Biosciences may need to refine its approach to address the hurdles presented in this study.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.